The vancomycin plus amikacin regimen (Group C) was associated with lower rates of ESR, CRP, colonization, and clinical infection (Table 2), potentially due to its broader Gram-positive coverage, including MRSA, compared to cefazolin [5, 7]. Here, CRP is linked to infection.